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Alma-Ata Declaration - 1978 
TODAY? 
“… the Primary Health Care… forms an integral part both 
of the country’s health system, of which it is the central 
function and main focus, and of the overall social and 
economic development of the community. It is the first level 
of contact… with the national health system, bringing 
health care as close as possible to where people live 
and work, and constitutes the first element of a 
continuing health care service…” 
As a result, medicines regulation was not carried out to 
the full extent required to ensure the quality, efficacy 
and safety of medicines in African countries. The findings 
confirm the results of a 2004 questionnaire survey 
conducted by WHO in 38 African member states, which 
found that 90% of countries did not provide or enforce 
adequate regulatory functions 
2005 Problem to be addressed 
2010 
The World Health Report 2006 - working together for health 
Chapter 1: Health workers: a global profile 
ACCESS TO HEALTH SERVICES:  
INEQUALITIES BETWEEN NORTH AND SOUTH OF THE WORLD 
«…water-borne diseases are not caused by lack of antibiotics but by 
dirty water, and by the political, social, and economic forces that fail to 
make clean water available to all; heart disease is caused not by a lack 
of coronary care units but by the lives people lead, which are shaped 
by the environments in which they live; obesity is not caused by moral 
failure on the part of individuals but by the excess availability of high-fat 
and high-sugar foods …» 
Borana Singing wells, Kenya 
PROBLEMS RELATED TO THE LIFE STILE 
“Closing the gap in a generation: Health equity through action on the 
social determinants of health” – WHO Commission on Social 
Determinants of Health - 2008 
Essential medicines are those that satisfy the priority health care needs of the 
population. They are selected with due regard to public health relevance, evidence on 
efficacy and safety, and comparative cost-effectiveness. 
Essential medicines are intended to be available within the context of functioning health 
systems at all times in adequate amounts, in the appropriate dosage forms, with 
assured quality and adequate information, and at a price the individual and the 
community can afford. 
ESSENTIAL MEDICINES  
 More than fifty percent of the population in the Region have no regular access to 
essential medicines.  
 Medicine supply and regulatory systems are weak 
 Financial as well as human resources are inadequate to ensure delivery of pharmaceutical 
services and ensure access to essential medicines.  
 Circulation of poor quality medicines, high medicine prices, unethical promotion and 
irrational use of medicines poses additional challenges. 
BUT… 
“IMPERFECT” COUNTERFEITS 
«these products contain the right components, with an 
incorrect concentration and/or formulation resulting in 
defective quality specifications. In the vast majority of cases, 
they are devoid of any therapeutic efficacy» 
COUNTERFEIT MEDICINES 
“CRIMINAL” COUNTERFEITS 
«they are apparently similar to the original medicinal product, 
but do not contain any active ingredient and can even include 
harmful or toxic substances. They are usually sold at high 
prices and for the treatment of serious pathologies. 
Consequences for users of criminal counterfeits can be fatal» 
Di Giorgio D. Counterfeit drugs. The phenomenon and 
enforcement activities. Milano: Tecniche nuove; 2010. 
А counterfeit medicine is one which is deliberately and fraudulently mislabeled with 
respect to identity and/or source. Counterfeiting can apply to both branded and generic 
products and counterfeit products may include products with the correct ingredients or with the 
wrong ingredients, without active ingredients, with insufficient active ingredients or with fake 
packaging. WHO - General information on counterfeit medicines 
F.Baratta, A. Germano, P. Brusa 
 
Diffusion of counterfeit drugs in 
developing Countries and stability 
of galenics stored for months 
under different conditions of 
temperature and relative humidity 
 
Croat Med J. 2012; 53: 173-184 
Analysis of 
196 samples 
of medicinal 
products 
COUNTERFIET MEDICINES IN DC: ANALYSIS OF THE PHENOMENON 
F.Baratta, A. 
Germano, P. Brusa 
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CAMEROUN 2012 
CAMEROUN 2013 
37% 
47% 
PHARMACEUTICAL FORMS TESTS (Ph Eur) 
 Uniformity of content (2.9.6) 
 Uniformity of mass (2.9.5) 
 Disintegration (2.9.1) 
 Friability (2.9.7) 
 Hardness (2.9.8) 
 Sterility (2.6.1) 
16% 
32% 
65% 
3% 
CAMEROUN 2013 
 Population: 20 million 
 Pharmacies on the national territory: 331 
 Yaoundé+Douala: 81 pharmacies 
 
HOW MANY ARE THE  
STREET VENDORS? 
PRELIMINARY RESULTS:  
 
1047 FAMILIES LIVING IN YAOUNDÉ: THE 99.6%, EVEN IF SCHOOLED, BUY MEDICINAL 
PRODUCTS BY STREET VENDORS 
 
 THE 34% OF SUBJECTS IS AWARE OF THE RISKS. THE 60% BUY THESE PRODUCTS DUE 
TO FINANCIAL DIFFICULTIES  
 
74 STREET VENDORS HAVE BEEN INTERVIEWED: THE 80% IS MEDIUM-HIGH CULTURAL 
GRADE 
www.progettoappa.it                 appa.onlus@unito.it 
A.P.P.A.® PROJECT 
PLANNING, CARRYING OUT, STARTING LABS IN ORDER TO PREPARE GALENIC 
MEDICINAL PRODUCTS AND RELATIVE QUALITY CONTROL IN DEVELOPING 
COUNTRIES  
 
FEDERAZIONE ORDINI 
FARMACISTI ITALIANI 
ORDINE DEI FARMACISTI 
PROVINCIA DI TORINO  
With the patronage of: 
and 
Choice of the place where building the galenic lab, choice of medicines needed and of the correct pharmaceutical 
forms, related to the local pathologies. 
Stage in A.P.P.A.® lab of Turin, for a Pharmacy’s student of Pharmacy Faculty of Turin; the stage leads to learn all 
the necessary to be able to prepare the programmed medicinal products. 
A technician of the Country holding the lab comes to Italy to learn the procedures of galenic medicines in A.P.P.A.® 
lab of Turin, under a Pharmacy’s student supervision. During this period the material needed for galenic lab will be 
sent to local partners. 
Training period in the chosen Country, during which the local technician, who has been in Italy to learn galenic 
methods and procedures, will be coordinated in his work by the Pharmacy’s student sent to the A.P.P.A.® lab . 
Quality control of medicinal products routinely prepared in new galenic lab; moreover some sample of these are 
sent to University of Turin, Pharmacy Faculty, where they are tested to verify their quality. 
Periodical stages at new lab for Pharmacy’s students of Pharmacy Faculty of Turin are performed each year both to 
give a continuous supervision of medicinal products prepared in the lab and to create new formulations according 
to the requests of  medical doctors responsable of the medical centers. 
PHASES  OF  A.P.P.A.  PROJECT 
Preliminary pharmaco-economic study which implies a trip of the A.P.P.A.® staff on site to value the local 
situation and recipient areas. Some medicines should be purchased in local pharmacies and sent to the 
laboratory of the University of Turin to value if these medicinal products, present on the local market, 
respect the declared characteristics or are counterfeit. 
Phase 
«zero» 
WHY GALENICS IN DC? 
USING LOCAL PERSONAL TEACHING THEM A JOB: 
AUTONOMY 
 
ALLOWING THE SALE OF CHEAP HIGH QUALITY 
MEDICINES   
 
AVOIDING THE PURCHASE OF MEDICINES 
ILLEGALLY IMPORTED 
 
CUSTOMIZING THE DOSAGES AND 
PHARMACEUTICAL FORMS ACCORDING TO THE 
ACTUAL NEEDS OF PATIENTS 
 HIGH PERCENTAGE OF COUNTERFEIT MEDICINES IN THE AREA 
 LOCAL POOR AVAILABILITY OF QUALITY MEDICINES   
 HIGH COST OF INDUSTRIAL MEDICINES 
 APPROVAL OF LOCAL AUTHORITIES 
 
BASIC CONDITIONS FOR OPENING 
A LAB FOR THE PREPARATION OF GALENIC MEDICINAL PRODUCTS 
Garouà - Cameroun N’Djamena - Tchad 
ENDEMIC DESEASES IN THE AREA 
• MALARIA 
• SALMONELLA 
• VENEREAL DESEASES 
• HEPATITIS A,B,C,D,E, 
• HIV 
• TUBERCULOSIS 
• OTHERS 
CHOICE OF THERAPEUTIC CLASSES FOR THE GALENIC LAB 
•    ANTIMALARALS 
•    TOPICAL ANTIFUNGAL 
•    TOPCAL AND SYSTEMIC ANTIBIOTICIS  
•    SYSTEMIC AND TOPICAL NSAD 
•    ANTIPYRETICS 
•    ANTIPARASITICS (antihelmintics, antiamebic, scabicidi) 
•    DISINFECTANTS 
FORMULATION PHARMACEUTICAL FORM 
ORAL SOLID OINTMENT FOR SKIN 
APPLICATION 
LIQUID 
• ORAL 
• FOR SKIN 
APPLICATION 
AIM 
The project was born from the need and the desire to teach a trade to people leaving in Developing 
Countries and to ensure the production of safe and effective medicines 
EASIER ACCESS TO MEDICINES 
DECREASE MORTALITY 
AFRICA: HIGH PRESENTS OF 
COUNTERFEIT MEDICINES 
NO THERAPEUTIC 
EFFECT 
CASES OF 
INTOXICATION 
SUPPOSITORY 
A.P.P.A.® LABS HANDBOOK 
SEMISOLID PREPARATIONS FOR CUTANEOUS 
APPLICATION 
LIQUID PREPARATIONS FOR CUTANEOUS 
APPLICATION 
SOLID PREPARATIONS 
LIQUID PREPARATIONS FOR ORAL USE 
Solutions 
Suspension 
Syrups 
Drops 
ORAL GEL 
POWDER FOR ORAL USE 
RECTAL PREPARATIONS 
STERILE PREPARATIONS 
Large volume parenteral solutions 
101 
FORMULATIONS 
HAITI: WHY? 
SAINT DAMIEN PAEDIATRIC HOSPITAL 
PORT-AU-PRINCE - HAITI 
MEDICINAL PRODUCTS 
LOT API PROVENANCE RESULTS 
6C090 Acetazolamide 250 mg Haiti 
Unsatisfied:  
Uniformity of content  (2.9.6), Friability (2.9.7) 
0302609 Ampicillin 1g India 
Unsatisfied: 
Bacterial endotixins (2.6.14.) 
071202 Chloramphenicol  1g USA Suitable 
09K4840 A Phenobarbital 30 mg Haiti 
Unsatisfied: 
Friability (2.9.7), Hardness (2.9.8) 
08E2978-A Phenobarbital syrup 18mg/5ml Haiti Suitable 
08111487 Propanolol 40mg Brasil 
Unsatisfied:  
Uniformity of content (2.9.6) 
L08111487 Spironolactone 25mg Domenican Republic Suitable 
PROBLEMS: 
 Method of preparation 
 Quality of industrial tablets 
 Stability of the preparations 
 Administration of capsules for the neonatal 
and paediatric treatment 
 
PREPARATION OF CAPSULES FOR CHILDREN 
FROM INDUSTRIAL HIGH-DOSE TABLETS 
PAEDIATRICS: WHY? 
CAPSULES PRODUCED IN 2010 
LOT API PROVENANCE RESULTS 
200910-A Acetazolamide 25 mg St Damien Hospital 
Unsatisfied:  
Uniformity of content (2.9.6) 
A-200S10-A Acetazolamide 25 mg St Damien Hospital Suitable 
121110-B Exp Captopril 1,25 mg St Damien Hospital 
Unsatisfied:  
Uniformity of mass (2.9.5) 
230610-C Phenytoin 10 mg St Damien Hospital Suitable 
230610-G Phenytoin 10 mg St Damien Hospital Suitable 
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 STUDY AND FORMULATION OF ORAL LIQUID PAEDIATRIC 
FORMULATIONS: METHODOLOGICAL  APPROACH 
A.P.P.A.® GALENIC LAB IN HAITI:  
SAINT DAMIEN PAEDIATRIC HOSPITAL 
In agreement whit local medical doctors the drugs for the paediatric therapy 
are chosen and then formulated: liquid oral formulations are preferred and 
appropriate excipients are selected. 
 
For each formulation a specific card (written in local language) has been 
prepared. The card shows the procedure of preparation and the characteristics 
of each component present in the formulation. 
 
Each preparation have been tested to check its quality and its stability 
under different environmental conditions in accordance with the EMA 
guidelines.  
PREPARATIONS PEDIATRIQUES 
SIROPS 
ACIDE ASCORBIQUE 10 mg/ml 
CANREONATE  DE POTASSIUM 1 mg/ml 
FER SULFATE 5 mg/ml 
IBUPROFENE 20 mg/ml 
PROPANOLOL 0,5 mg/ml 
RANITIDINE 15 mg/ml 
SALBUTAMOL 0,4 mg/ml 
VITAMINE B6 1 mg/ ml 
SOLUTIONS 
CAPTOPRIL 1 mg/ml 
FUROSEMIDE 1 mg/ml 
GOUTTES 
NIFEDIPINE 1 mg/gtt 
RANITIDINE  4 mg/gtt 
SALBUTAMOL 0,2 mg/gtt 
VITAMINE B6 0,5 mg/gtt 
SUSPENSIONS 
VITAMINE B COMPLEX 5,8 mg/ml 
MAGNESIUM ET ALUMINIUM HYDROXYDE 200 
mg/ml 
Saint Damien Hospital 
0 
STABILITY STUDY OF THE PREPARED  
LIQUID PHARMACEUTICAL FORMS 
STORAGE  
CONDITION 
T (°C) RH PERIOD COVERED BY DATA ANALYTICAL METHOD 
Standard 25±2 60±5% 
12 months, analysis at time zero (T0) 
and every 30 days  
(from TS-1 to TS-12) 
UV-VIS 
spectrophotometric assay 
Refrigerator 5±3 - 
12 months, analysis at time zero (T0) 
and every 30 days  
(from TR-1 to TR-12) 
Accelerated 40±2 60±5% 
3 months, analysis at time zero (T0) 
and every 30 days  
(from TA-1 through TA-3) 
EMA Guideline on stability testing: stability testing of existing active substances and related finished products, 
2003, CPMP/QWP/122/02, rev 1 corr 
A.P.P.A.® GALENIC LAB IN HAITI 
Method: 
EVALUATION OF THE EXPIRATION DATE 
VALIDITY PERIOD:  
3 MONTHS 
housing and environmental conditions 
are not suitable for a proper storage of 
the preparations 
BUT 
The stability has been 
demonstrated  
for 12 MONTHS for  
all formulations 
PREPARATIONS PEDIATRIQUES 
SIROPS 
ACIDE ASCORBIQUE 10 mg/ml 
CANREONATE  DE POTASSIUM 1 mg/ml 
FER SULFATE 5 mg/ml 
IBUPROFENE 20 mg/ml 
PROPANOLOL 0,5 mg/ml 
RANITIDINE 15 mg/ml 
SALBUTAMOL 0,4 mg/ml 
VITAMINE B6 1 mg/ ml 
SOLUTIONS 
CAPTOPRIL 1 mg/ml 
FUROSEMIDE 1 mg/ml 
GOUTTES 
NIFEDIPINE 1 mg/gtt 
RANITIDINE  4 mg/gtt 
SALBUTAMOL 0,2 mg/gtt 
VITAMINE B6 0,5 mg/gtt 
SUSPENSIONS 
VITAMINE B COMPLEX 5,8 mg/ml 
MAGNESIUM ET ALUMINIUM HYDROXYDE 200 mg/ml 
STABILITY STUDY: RESULTS 
PAEDIATRIC FORMULATIONS: NON ONLY IN HAITI 
EXTEMPORANEOUS SUSPENSION FOR ORAL USE 
SUPPOSITORY 
Galenics, in accord with the European Law (Ph Eur,), must guarantee “the quality 
as a fundamental support to the security and the efficacy” 
PHARMACEUTICAL FORMS TESTS (Ph Eur) 
Uniformity of content (2.9.6) 
Uniformity of mass (2.9.5) 
Disintegration (2.9.1) 
Friability (2.9.7) 
Hardness (2.9.8) 
Sterility (2.6.1) 
STABILITY TESTS 
(EMA) 
D.C. 
ITALY 
PHARMACEUTICAL FORMS TESTS 
 
Ointments for skin application; Suppositories: 
•Verify of accuracy of followed procedures 
•Control of aspect 
•Control of the amount to sell 
•Control of the solidity of packing 
 
Stiff capsules: 
•Verify the accuracy of followed procedures 
•Control of aspect and solidity of capsules 
•Control of the number of capsules prepared 
•Mass uniformity of capsules 
 
Liquid medicinal products: 
•Verify the accuracy of followed procedures 
•Control of the amount of product to sell 
•Control of the solidity of packing 
RAW MATERIALS: Organoleptic control  
Melting point  
QUALITY CONTROL AND QUALITY ASSURANCE 
QUALITY CONTROL AND QUALITY ASSURANCE 
ANALYSIS METHOD REF. ACCEPTANCE CRITERIA 
General aspect Visual Posological unit integrity 
Uniformity of 
content 
Ph. Eur. 7 ed. 
Assay 2.9.6 
Each individual content is between 85% and 115% of the average 
content (10 dosage units) 
Uniformity of 
mass 
Ph. Eur. 7 ed. 
Assay 2.9.5 
Not more than two of the individual masses deviate from the average 
mass by more than ± 10% and none deviates by more than ±20% (20 
dosage units) 
Disintegration 
Ph. Eur. 7 ed. 
Assay 2.9.1 
At the end of the specified time all of the dosage units must have 
disintegrated completely 
Friability 
Ph. Eur. 7 ed. 
Assay 2.9.7 
Maximum loss of mass not more than 1% 
Hardness 
Ph. Eur. 7 ed. 
Assay 2.9.8 
Hardness between 3 and 12 N 
Sterility test  
Ph. Eur. 7 ed. 
Assay 2.6.1 
At intervals during the incubation period and at its conclusion, examine 
the media for macroscopic evidence of microbial growth: If no 
evidence of microbial growth is found, the product to be examined 
complies with the test for sterility 
Bacterial 
endotoxins  
Ph. Eur. 7 ed. 
Assay 2.6.14 
The test is considered valid when all replicates of tested solutions 
show no reaction and the result of control solution confirms the 
labelled lysate sensitivity. 
STANDARDIZATION OF RESULTS  
LOW COSTS 
SIMPLE EXECUTION 
SPECTOPHOTOMETRY UV/VIS 
“…reuse, repair equipment and goods instead of throwing them in a landfill, exceeding the 
consumerist obsession of the obsolescence of objects and the tension to the new…”  
A. Salza “Niente. Come si vive quando manca tutto. Antropologia della povertà estrema”, 
Sperling & Kupfer 2009 
A.P.P.A.®  LABS IN THE WORLD 
ANGOLA – Cubal, Nossa Senhora de Paz hospital, Compañia de Santa Teresa de Jesus.  
ANGOLA – Funda, A.M.E.N. ONG health care facility. 
CAMERUN – Douala, La Bethanie hospital. 
CAMERUN – Garoua, Notre Dame des Apôtres hospital, Djamboutou. 
CIAD – N’Djamena, Le Bon Samaritain hospital. 
HAITI – Tabarre Chateaublond, N.P.H. Saint Damien paediatric hospital. 
MADAGASCAR – Vohipeno, Henintsoa hospital. 
MADAGASCAR – Ihosy, Eglise Catholique Apostolique Romaine medical center. 
CAMEROUN 
Douala  
Garoua 
ANGOLA  
Funda 
 Cubal 
TCHAD 
N’Djamena 
MADAGASCAR 
Ihosy  
Vohipeno 
HAITI 
Port au Prince 
8 GALENICS LABS IN DEVELOPING COUNTRIES 
 
 
ECONOMIC INVESTMENT IN RAW MATERIALS: ≈ 100.000 €  
 
ADMINISTERED DOSES:  
i.e. cps ≈ 7.500.000  
A GOOD REASON TO GO ON 
  BUT WITH THE AIM OF  
BECOME LESS AND LESS INDISPENSABLES 
A.P.P.A.® 2005-2013 
